Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-based Heparin Anti-Xa Monitoring in Surgery
NCT03516656Phase 1Completed
- Sponsor
- University of Utah
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of heparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by University of Utah. Primary endpoint: Percentage of Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL) at 1 year. Started Mar 2018; status: completed.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03516656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516656.